Adalimumab (Humira): a brief review for dermatologists (Q36069543)

12 August 2017

1 reference

title

Adalimumab (Humira): a brief review for dermatologists (English)

1 reference

12 August 2017

0 references

N Scheinfeld

1

1 reference

12 August 2017

publication date

1 December 2004

1 reference

Journal of Dermatological Treatment

12 August 2017

published in

1 reference

12 August 2017

volume

15

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

348-352

1 reference

Strategies for targeting tumour necrosis factor in IBD.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017284

Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017284

Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017284

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017284

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017284

Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09546630410017284

10.1080/09546630410017284

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference